COVID-19 Vaccination in Patients With Inflammatory Bowel Disease and History of Reaction to Injectable Therapies

Safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systematic review and meta-analysis

“…The details of the included studies are illustrated in Table 1 [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] . The details of the excluded studies with the reason for exclusion is shown in Supplementary Table 2 [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] .

Figure 1 PRISMA flow chart depicting the study screening and selection of the systematic review

…”

Risk, Course, and Effect of SARS-CoV-2 Infection in Children and Adults with Chronic Inflammatory Bowel Diseases

“…PEG’s structure is similar to that of polysorbate, and this leads to possible cross-reactions that could explain the Jannsen’s case of hypersensibility. It is noteworthy that various biologics contain polysorbate 80 as excipient: it is the case of Infliximab, Adalimumab, Golimumab, Natalizumab, Ustekinumab, and Vedolizumab [ 108 ]. In fact, several immediate hypersensitivity reactions are reported after taking Infliximab [ 109 ].…”